Hematological Cancers Market By Type (Leukemia (Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), & Others), Lymphoma (Hodgkin's Lymphoma & Non-Hodgkin's Lymphoma), Myeloma, and Others (Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN)); By Treatment Type (Stem Cell Transplantation, Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Radiosurgery, and Others); By Administration (Oral, Intravenous, Intra-Muscular, Intrathecal, Local Therapies (Surgery, Radiation Therapy, Topical Therapy, Etc.), and Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Hematologic cancers, commonly referred to as blood cancers, affect the production and function of blood cells. Usually beginning in the bone marrow, they cause the overproduction of an abnormal type of cell. Although blood cancer cells do not form solid tumors, they lead to overcrowding of abnormal cells in the blood, bone marrow or plasma, preventing normal cells from developing and performing important functions. According to a study, approximately 32,000 Americans get diagnosed with multiple myeloma each year. Many factors are driving the global hematological cancers market but the most important factor is growing awareness pertaining to early diagnosis of hematological cancer. High prevalence rate of these hematological malignancies can be attributed to rapid population growth and aging. Rising prevalence of hematological malignancies is another major factor that is contributing towards the growth of this market. Other factors driving the market growth include advancement in medical sector, feasibility of early treatment due to early diagnosis, new product launches in medical sector, increasing survival rate of the population suffering from blood cancer, and increased government support for research & development. Lack of awareness about different types of cancers and early diagnosis in developing countries as well as underdeveloped countries is restraining the growth of global hematological cancers market.
The COVID-19 pandemic has led to a tremendous rise in concern because cancer can harm coronavirus patients more severely. According to a study in Wuhan, China where coronavirus originated, two studies were conducted which concluded that the effects and symptoms of hematological cancers were more severe in patients effected with COVID-19, compared to hematological cancer patients who were not infected with COVID-19. The rising demand for hematological cancers treatments globally is fuelling investment, research, and adoption of medical services, which is anticipated to boost the growth of global hematological cancers market over the forecast period. Absolute Market Insights reports, the global hematological cancers market is likely to grow at 10.1% CAGR during the 2021-2029 period, and reach a valuation of US$ 107.93 Bn by 2029.
Global Hematological Cancers Market Revenue & Forecast, (US$ Billion), 2015 – 2029
Type Outlook:
By type, the global hematological cancers market is classified into leukemia, lymphoma, myeloma, and others. Leukemia has been further segmented into acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and others. Lymphoma has been further segmented into Hodgkin’s lymphoma and Non-Hodgkin's lymphoma. In 2020, leukemia category held the largest market share and during the forecast period, this category is expected to retain its slot and become the fastest growing category in the market. All cancers located in the blood and bone marrow due to the overproduction of abnormal white blood cells are categorized as leukemia. ALL is a fast-growing leukemia and it requires immediate attention because it worsens quickly. During leukemia, the bone marrow produces an excessive amount of abnormal white blood cells that do not function properly. Chronic leukemia grows slowly compared to acute leukemia and it takes longer to advance. Rapid treatment requirement and early diagnosis is fuelling the segment’s growth in the global market.
Treatment Type Outlook:
The treatment type segment in the global hematological cancers market has been broadly segmented into stem cell transplantation, chemotherapy, targeted therapy, immunotherapy, radiation therapy, radiosurgery, and others. During the forecast period, immunotherapy treatment type is anticipated to grow rapidly. Immunotherapy treatment can boost or restore the ability of the immune system to fight cancer, infections, and other ailments. In a patient's body, the disease-fighting immune system may not attack his/her cancer because the cancer cells produce proteins that help them hide from the immune system cells. Immunotherapy prevents this and is also used to reduce certain side effects that may be caused by some cancer treatments. Working against many types of cancer, the immunotherapy offers possibility of long-term cancer remission and the patient is less likely to experience side effects of other treatments.
Administration Outlook:
The global hematological cancers market is classified into oral administration, intravenous administration, intra-muscular administration, intrathecal administration, local therapies (surgery, radiation therapy, topical therapy, etc.) and others. In 2020, the local therapies (surgery, radiation therapy, topical therapy, etc.) category held the larger market share.
The intravenous administration category is gaining traction in the global hematological cancers market. Availability of medicines like Sarclisa is also boosting the growth of this category. In combination with many medicines, this medicines facilitates a treatment cycle of 28 days. As most biomimetic nanoparticles (NPs) are designed to treat hematologic malignancies, they need to be administered systemically by intravenous administration, in order to ensure that they must have minimal harmful effects on healthy blood cells. Intravenous nutrition or antiemetic (anti-vomiting) therapy is helpful to patients who experience side effects that render them unable to eat or drink anything without vomiting. Approval of medicines like intravenous (IV) rituximab is also boosting the market growth.
Region Outlook:
In 2020, North America accounted for the highest share in the global hematological cancers market. During the forecast period, Asia Pacific region is expected witness highest growth rate. Countries like China and India are witnessing alarming rise in number of Cancer patients. India, for instance, registers nearly 1.5 million cases of different types of hematological cancers every year. Furthermore, factors such as advancement in technologies, increasing prevalence of blood-related disorders, increase in healthcare expenditure, rising R&D expenditure, and high unmet clinical needs of patients in developing countries is anticipated to supplement the region’s growth over the period of next eight years.
Competitive Landscape Outlook:
The global hematological cancers market landscape remains a highly innovative, competitive, and fragmented. Despite major investments from many big players in the medical sector, most companies do not account for a sizable market share to influence pricing. Furthermore, the barriers to entry are financial in nature because hematological cancer treatment is expensive and as there are different types of blood cancers, some cancers require time-consuming treatment that are more expensive. Some key players in the global hematological cancers market are AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, HK inno.N Corp., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Company Limited amongst others.
Global Hematological Cancers Market:
By Type
- Leukemia
- Acute Lymphocytic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Others
- Lymphoma
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Myeloma
- Others (Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN))
By Treatment Type
- Stem Cell Transplantation
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy
- Radiosurgery
- Others
By Administration
- Oral
- Intravenous
- Intra-Muscular
- Intrathecal
- Local Therapies (Surgery, Radiation Therapy, Topical Therapy, Etc.)
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2020
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Hematological Cancers Market
6. Market Synopsis:
Hematological Cancers Market
7. Hematological Cancers Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Hematological Cancers Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Hematological Cancers Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
COVID-19 on Hematological Cancers Market
8. Global Hematological Cancers Market Analysis and Forecasts,
2021 – 2029
8.1. Overview
8.1.1. Global
Hematological Cancers Market Revenue (US$ Mn)
8.2. Global
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Leukemia
(Definition, Market Estimation and Penetration, 2015 - 2020, Market Estimation
(2015 - 2020), Market Forecast (2021 – 2029), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Acute Lymphocytic Leukemia (ALL),
Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic
Myeloid Leukemia (CML), Others)
8.2.1.1. Acute
Lymphocytic Leukemia (ALL)
8.2.1.2. Chronic
Lymphocytic Leukemia (CLL)
8.2.1.3. Acute
Myeloid Leukemia (AML)
8.2.1.4. Chronic
Myeloid Leukemia (CML)
8.2.1.5. Others
8.2.2. Lymphoma
(Definition, Market Estimation and Penetration, 2015 - 2020, Market Estimation
(2015 - 2020), Market Forecast (2021 – 2029), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Hodgkin's Lymphoma, Non-Hodgkin's
Lymphoma)
8.2.2.1. Hodgkin's
Lymphoma
8.2.2.2. Non-Hodgkin's
Lymphoma
8.2.3. Myeloma
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 - 2020
8.2.3.3. Market
Forecast, 2021 – 2029
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2020
8.2.3.5.1.2. Market
Forecast, 2021 – 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2020
8.2.3.5.2.2. Market
Forecast, 2021 – 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2020
8.2.3.5.3.2. Market
Forecast, 2021 – 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2020
8.2.3.5.4.2. Market
Forecast, 2021 – 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2020
8.2.3.5.5.2. Market
Forecast, 2021 – 2029
8.2.4. Others
(Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN))
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2015 - 2020
8.2.4.3. Market
Forecast, 2021 – 2029
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2020
8.2.4.5.1.2. Market
Forecast, 2021 – 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2020
8.2.4.5.2.2. Market
Forecast, 2021 – 2029
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2020
8.2.4.5.3.2. Market
Forecast, 2021 – 2029
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2020
8.2.4.5.4.2. Market
Forecast, 2021 – 2029
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2020
8.2.4.5.5.2. Market
Forecast, 2021 – 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Hematological Cancers Market Analysis and Forecasts,
2021 – 2029
9.1. Overview
9.2. Global
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
9.2.1. Stem
Cell Transplantation
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 - 2020
9.2.1.3. Market
Forecast, 2021 – 2029
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2020
9.2.1.5.1.2. Market
Forecast, 2021 – 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2020
9.2.1.5.2.2. Market
Forecast, 2021 – 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2020
9.2.1.5.3.2. Market
Forecast, 2021 – 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2020
9.2.1.5.4.2. Market
Forecast, 2021 – 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2020
9.2.1.5.5.2. Market
Forecast, 2021 – 2029
9.2.2. Chemotherapy
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 - 2020
9.2.2.3. Market
Forecast, 2021 – 2029
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 – 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 – 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 – 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 – 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2020
9.2.2.5.5.2. Market
Forecast, 2021 – 2029
9.2.3. Targeted
Therapy
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 - 2020
9.2.3.3. Market
Forecast, 2021 – 2029
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2020
9.2.3.5.1.2. Market
Forecast, 2021 – 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2020
9.2.3.5.2.2. Market
Forecast, 2021 – 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2020
9.2.3.5.3.2. Market
Forecast, 2021 – 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2020
9.2.3.5.4.2. Market
Forecast, 2021 – 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2020
9.2.3.5.5.2. Market
Forecast, 2021 – 2029
9.2.4. Immunotherapy
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2015 - 2020
9.2.4.3. Market
Forecast, 2021 – 2029
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2020
9.2.4.5.1.2. Market
Forecast, 2021 – 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2020
9.2.4.5.2.2. Market
Forecast, 2021 – 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2020
9.2.4.5.3.2. Market
Forecast, 2021 – 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2020
9.2.4.5.4.2. Market
Forecast, 2021 – 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2020
9.2.4.5.5.2. Market
Forecast, 2021 – 2029
9.2.5. Radiation
Therapy
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2015 - 2020
9.2.5.3. Market
Forecast, 2021 – 2029
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2020
9.2.5.5.1.2. Market
Forecast, 2021 – 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2020
9.2.5.5.2.2. Market
Forecast, 2021 – 2029
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2020
9.2.5.5.3.2. Market
Forecast, 2021 – 2029
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2020
9.2.5.5.4.2. Market
Forecast, 2021 – 2029
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2020
9.2.5.5.5.2. Market
Forecast, 2021 – 2029
9.2.6. Radiosurgery
9.2.6.1. Definition
9.2.6.2. Market
Estimation and Penetration, 2015 - 2020
9.2.6.3. Market
Forecast, 2021 – 2029
9.2.6.4. Compound
Annual Growth Rate (CAGR)
9.2.6.5. Regional
Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market
Estimation, 2015 - 2020
9.2.6.5.1.2. Market
Forecast, 2021 – 2029
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2020
9.2.6.5.2.2. Market
Forecast, 2021 – 2029
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2020
9.2.6.5.3.2. Market
Forecast, 2021 – 2029
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2020
9.2.6.5.4.2. Market
Forecast, 2021 – 2029
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market
Estimation, 2015 - 2020
9.2.6.5.5.2. Market
Forecast, 2021 – 2029
9.2.7. Others
9.2.7.1. Definition
9.2.7.2. Market
Estimation and Penetration, 2015 - 2020
9.2.7.3. Market
Forecast, 2021 – 2029
9.2.7.4. Compound
Annual Growth Rate (CAGR)
9.2.7.5. Regional
Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market
Estimation, 2015 - 2020
9.2.7.5.1.2. Market
Forecast, 2021 – 2029
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 - 2020
9.2.7.5.2.2. Market
Forecast, 2021 – 2029
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market
Estimation, 2015 - 2020
9.2.7.5.3.2. Market
Forecast, 2021 – 2029
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 - 2020
9.2.7.5.4.2. Market
Forecast, 2021 – 2029
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market
Estimation, 2015 - 2020
9.2.7.5.5.2. Market
Forecast, 2021 – 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Treatment Type
10. Global Hematological Cancers Market Analysis and Forecasts,
2021 – 2029
10.1. Overview
10.2. Global
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
10.2.1. Oral
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 - 2020
10.2.1.3. Market
Forecast, 2021 – 2029
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2020
10.2.1.5.1.2. Market
Forecast, 2021 – 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2020
10.2.1.5.2.2. Market
Forecast, 2021 – 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2020
10.2.1.5.3.2. Market
Forecast, 2021 – 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2020
10.2.1.5.4.2. Market
Forecast, 2021 – 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2020
10.2.1.5.5.2. Market
Forecast, 2021 – 2029
10.2.2. Intravenous
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 - 2020
10.2.2.3. Market
Forecast, 2021 – 2029
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2020
10.2.2.5.1.2. Market
Forecast, 2021 – 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2020
10.2.2.5.2.2. Market
Forecast, 2021 – 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2020
10.2.2.5.3.2. Market
Forecast, 2021 – 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2020
10.2.2.5.4.2. Market
Forecast, 2021 – 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2020
10.2.2.5.5.2. Market
Forecast, 2021 – 2029
10.2.3. Intra-Muscular
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 - 2020
10.2.3.3. Market
Forecast, 2021 – 2029
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2020
10.2.3.5.1.2. Market
Forecast, 2021 – 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2020
10.2.3.5.2.2. Market
Forecast, 2021 – 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2020
10.2.3.5.3.2. Market
Forecast, 2021 – 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2020
10.2.3.5.4.2. Market
Forecast, 2021 – 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2020
10.2.3.5.5.2. Market
Forecast, 2021 – 2029
10.2.4. Intrathecal
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2015 - 2020
10.2.4.3. Market
Forecast, 2021 – 2029
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2020
10.2.4.5.1.2. Market
Forecast, 2021 – 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2020
10.2.4.5.2.2. Market
Forecast, 2021 – 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2020
10.2.4.5.3.2. Market
Forecast, 2021 – 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2020
10.2.4.5.4.2. Market
Forecast, 2021 – 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2020
10.2.4.5.5.2. Market
Forecast, 2021 – 2029
10.2.5. Local
Therapies (Surgery, Radiation Therapy, Topical Therapy, Etc.)
10.2.5.1. Definition
10.2.5.2. Market
Estimation and Penetration, 2015 - 2020
10.2.5.3. Market
Forecast, 2021 – 2029
10.2.5.4. Compound
Annual Growth Rate (CAGR)
10.2.5.5. Regional
Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market
Estimation, 2015 - 2020
10.2.5.5.1.2. Market
Forecast, 2021 – 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 - 2020
10.2.5.5.2.2. Market
Forecast, 2021 – 2029
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market
Estimation, 2015 - 2020
10.2.5.5.3.2. Market
Forecast, 2021 – 2029
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 - 2020
10.2.5.5.4.2. Market
Forecast, 2021 – 2029
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market
Estimation, 2015 - 2020
10.2.5.5.5.2. Market
Forecast, 2021 – 2029
10.2.6. Others
10.2.6.1. Definition
10.2.6.2. Market
Estimation and Penetration, 2015 - 2020
10.2.6.3. Market
Forecast, 2021 – 2029
10.2.6.4. Compound
Annual Growth Rate (CAGR)
10.2.6.5. Regional
Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market
Estimation, 2015 - 2020
10.2.6.5.1.2. Market
Forecast, 2021 – 2029
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2015 - 2020
10.2.6.5.2.2. Market
Forecast, 2021 – 2029
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market
Estimation, 2015 - 2020
10.2.6.5.3.2. Market
Forecast, 2021 – 2029
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market
Estimation, 2015 - 2020
10.2.6.5.4.2. Market
Forecast, 2021 – 2029
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market
Estimation, 2015 - 2020
10.2.6.5.5.2. Market
Forecast, 2021 – 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Administration
11. North America Hematological Cancers Market Analysis and
Forecasts, 2020 - 2028
11.1. Overview
11.1.1. North
America Hematological Cancers Market Revenue (US$ Mn)
11.2. North
America Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
11.2.1. Leukemia
11.2.1.1. Acute
Lymphocytic Leukemia (ALL)
11.2.1.2. Chronic
Lymphocytic Leukemia (CLL)
11.2.1.3. Acute
Myeloid Leukemia (AML)
11.2.1.4. Chronic
Myeloid Leukemia (CML)
11.2.1.5. Others
11.2.2. Lymphoma
11.2.2.1. Hodgkin's
Lymphoma
11.2.2.2. Non-Hodgkin's
Lymphoma
11.2.3. Myeloma
11.2.4. Others
(Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN))
11.3. North
America Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
11.3.1. Stem
Cell Transplantation
11.3.2. Chemotherapy
11.3.3. Targeted
Therapy
11.3.4. Immunotherapy
11.3.5. Radiation
Therapy
11.3.6. Radiosurgery
11.3.7. Others
11.4. North
America Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
11.4.1. Oral
11.4.2. Intravenous
11.4.3. Intra-Muscular
11.4.4. Intrathecal
11.4.5. Local
Therapies (Surgery, Radiation Therapy, Topical Therapy, Etc.)
11.4.6. Others
11.5. North
America Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
11.5.1.1.1. Leukemia
11.5.1.1.1.1. Acute
Lymphocytic Leukemia (ALL)
11.5.1.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
11.5.1.1.1.3. Acute
Myeloid Leukemia (AML)
11.5.1.1.1.4. Chronic
Myeloid Leukemia (CML)
11.5.1.1.1.5. Others
11.5.1.1.2. Lymphoma
11.5.1.1.2.1. Hodgkin's
Lymphoma
11.5.1.1.2.2. Non-Hodgkin's
Lymphoma
11.5.1.1.3. Myeloma
11.5.1.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
11.5.1.2. U.S
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
11.5.1.2.1. Stem Cell Transplantation
11.5.1.2.2. Chemotherapy
11.5.1.2.3. Targeted Therapy
11.5.1.2.4. Immunotherapy
11.5.1.2.5. Radiation Therapy
11.5.1.2.6. Radiosurgery
11.5.1.2.7. Others
11.5.1.3. U.S
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
11.5.1.3.1. Oral
11.5.1.3.2. Intravenous
11.5.1.3.3. Intra-Muscular
11.5.1.3.4. Intrathecal
11.5.1.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
11.5.1.3.6. Others
11.5.2. Canada
11.5.2.1. Canada
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
11.5.2.1.1. Leukemia
11.5.2.1.1.1. Acute
Lymphocytic Leukemia (ALL)
11.5.2.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
11.5.2.1.1.3. Acute
Myeloid Leukemia (AML)
11.5.2.1.1.4. Chronic
Myeloid Leukemia (CML)
11.5.2.1.1.5. Others
11.5.2.1.2. Lymphoma
11.5.2.1.2.1. Hodgkin's
Lymphoma
11.5.2.1.2.2. Non-Hodgkin's
Lymphoma
11.5.2.1.3. Myeloma
11.5.2.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
11.5.2.2. Canada
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
11.5.2.2.1. Stem Cell Transplantation
11.5.2.2.2. Chemotherapy
11.5.2.2.3. Targeted Therapy
11.5.2.2.4. Immunotherapy
11.5.2.2.5. Radiation Therapy
11.5.2.2.6. Radiosurgery
11.5.2.2.7. Others
11.5.2.3. Canada
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
11.5.2.3.1. Oral
11.5.2.3.2. Intravenous
11.5.2.3.3. Intra-Muscular
11.5.2.3.4. Intrathecal
11.5.2.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
11.5.2.3.6. Others
11.5.3. Mexico
11.5.3.1. Mexico
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
11.5.3.1.1. Leukemia
11.5.3.1.1.1. Acute
Lymphocytic Leukemia (ALL)
11.5.3.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
11.5.3.1.1.3. Acute
Myeloid Leukemia (AML)
11.5.3.1.1.4. Chronic
Myeloid Leukemia (CML)
11.5.3.1.1.5. Others
11.5.3.1.2. Lymphoma
11.5.3.1.2.1. Hodgkin's
Lymphoma
11.5.3.1.2.2. Non-Hodgkin's
Lymphoma
11.5.3.1.3. Myeloma
11.5.3.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
11.5.3.2. Mexico
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
11.5.3.2.1. Stem Cell Transplantation
11.5.3.2.2. Chemotherapy
11.5.3.2.3. Targeted Therapy
11.5.3.2.4. Immunotherapy
11.5.3.2.5. Radiation Therapy
11.5.3.2.6. Radiosurgery
11.5.3.2.7. Others
11.5.3.3. Mexico
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
11.5.3.3.1. Oral
11.5.3.3.2. Intravenous
11.5.3.3.3. Intra-Muscular
11.5.3.3.4. Intrathecal
11.5.3.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
11.5.3.3.6. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America Hematological Cancers Market Revenue (US$ Mn) and Forecasts,
By Type
11.5.4.1.1. Leukemia
11.5.4.1.1.1. Acute
Lymphocytic Leukemia (ALL)
11.5.4.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
11.5.4.1.1.3. Acute
Myeloid Leukemia (AML)
11.5.4.1.1.4. Chronic
Myeloid Leukemia (CML)
11.5.4.1.1.5. Others
11.5.4.1.2. Lymphoma
11.5.4.1.2.1. Hodgkin's
Lymphoma
11.5.4.1.2.2. Non-Hodgkin's
Lymphoma
11.5.4.1.3. Myeloma
11.5.4.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
11.5.4.2. Rest
of North America Hematological Cancers Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
11.5.4.2.1. Stem Cell Transplantation
11.5.4.2.2. Chemotherapy
11.5.4.2.3. Targeted Therapy
11.5.4.2.4. Immunotherapy
11.5.4.2.5. Radiation Therapy
11.5.4.2.6. Radiosurgery
11.5.4.2.7. Others
11.5.4.3. Rest
of North America Hematological Cancers Market Revenue (US$ Mn) and Forecasts,
By Administration
11.5.4.3.1. Oral
11.5.4.3.2. Intravenous
11.5.4.3.3. Intra-Muscular
11.5.4.3.4. Intrathecal
11.5.4.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
11.5.4.3.6. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By Type
11.6.3. By
Treatment Type
11.6.4. By
Administration
12. Europe Hematological Cancers Market Analysis and Forecasts,
2020 - 2028
12.1. Overview
12.1.1. Europe
Hematological Cancers Market Revenue (US$ Mn)
12.2. Europe
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Leukemia
12.2.1.1. Acute
Lymphocytic Leukemia (ALL)
12.2.1.2. Chronic
Lymphocytic Leukemia (CLL)
12.2.1.3. Acute
Myeloid Leukemia (AML)
12.2.1.4. Chronic
Myeloid Leukemia (CML)
12.2.1.5. Others
12.2.2. Lymphoma
12.2.2.1. Hodgkin's
Lymphoma
12.2.2.2. Non-Hodgkin's
Lymphoma
12.2.3. Myeloma
12.2.4. Others
(Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN))
12.3. Europe
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
12.3.1. Stem
Cell Transplantation
12.3.2. Chemotherapy
12.3.3. Targeted
Therapy
12.3.4. Immunotherapy
12.3.5. Radiation
Therapy
12.3.6. Radiosurgery
12.3.7. Others
12.4. Europe
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
12.4.1. Oral
12.4.2. Intravenous
12.4.3. Intra-Muscular
12.4.4. Intrathecal
12.4.5. Local
Therapies (Surgery, Radiation Therapy, Topical Therapy, Etc.)
12.4.6. Others
12.5. Europe
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
12.5.1.1.1. Leukemia
12.5.1.1.1.1. Acute
Lymphocytic Leukemia (ALL)
12.5.1.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
12.5.1.1.1.3. Acute
Myeloid Leukemia (AML)
12.5.1.1.1.4. Chronic
Myeloid Leukemia (CML)
12.5.1.1.1.5. Others
12.5.1.1.2. Lymphoma
12.5.1.1.2.1. Hodgkin's
Lymphoma
12.5.1.1.2.2. Non-Hodgkin's
Lymphoma
12.5.1.1.3. Myeloma
12.5.1.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
12.5.1.2. France
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
12.5.1.2.1. Stem Cell Transplantation
12.5.1.2.2. Chemotherapy
12.5.1.2.3. Targeted Therapy
12.5.1.2.4. Immunotherapy
12.5.1.2.5. Radiation Therapy
12.5.1.2.6. Radiosurgery
12.5.1.2.7. Others
12.5.1.3. France
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
12.5.1.3.1. Oral
12.5.1.3.2. Intravenous
12.5.1.3.3. Intra-Muscular
12.5.1.3.4. Intrathecal
12.5.1.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
12.5.1.3.6. Others
12.5.2. The UK
12.5.2.1. The
UK Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
12.5.2.1.1. Leukemia
12.5.2.1.1.1. Acute
Lymphocytic Leukemia (ALL)
12.5.2.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
12.5.2.1.1.3. Acute
Myeloid Leukemia (AML)
12.5.2.1.1.4. Chronic
Myeloid Leukemia (CML)
12.5.2.1.1.5. Others
12.5.2.1.2. Lymphoma
12.5.2.1.2.1. Hodgkin's
Lymphoma
12.5.2.1.2.2. Non-Hodgkin's
Lymphoma
12.5.2.1.3. Myeloma
12.5.2.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
12.5.2.2. The
UK Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment
Type
12.5.2.2.1. Stem Cell Transplantation
12.5.2.2.2. Chemotherapy
12.5.2.2.3. Targeted Therapy
12.5.2.2.4. Immunotherapy
12.5.2.2.5. Radiation Therapy
12.5.2.2.6. Radiosurgery
12.5.2.2.7. Others
12.5.2.3. The
UK Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
12.5.2.3.1. Oral
12.5.2.3.2. Intravenous
12.5.2.3.3. Intra-Muscular
12.5.2.3.4. Intrathecal
12.5.2.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
12.5.2.3.6. Others
12.5.3. Spain
12.5.3.1. Spain
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
12.5.3.1.1. Leukemia
12.5.3.1.1.1. Acute
Lymphocytic Leukemia (ALL)
12.5.3.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
12.5.3.1.1.3. Acute
Myeloid Leukemia (AML)
12.5.3.1.1.4. Chronic
Myeloid Leukemia (CML)
12.5.3.1.1.5. Others
12.5.3.1.2. Lymphoma
12.5.3.1.2.1. Hodgkin's
Lymphoma
12.5.3.1.2.2. Non-Hodgkin's
Lymphoma
12.5.3.1.3. Myeloma
12.5.3.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
12.5.3.2. Spain
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
12.5.3.2.1. Stem Cell Transplantation
12.5.3.2.2. Chemotherapy
12.5.3.2.3. Targeted Therapy
12.5.3.2.4. Immunotherapy
12.5.3.2.5. Radiation Therapy
12.5.3.2.6. Radiosurgery
12.5.3.2.7. Others
12.5.3.3. Spain
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
12.5.3.3.1. Oral
12.5.3.3.2. Intravenous
12.5.3.3.3. Intra-Muscular
12.5.3.3.4. Intrathecal
12.5.3.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
12.5.3.3.6. Others
12.5.4. Germany
12.5.4.1. Germany
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
12.5.4.1.1. Leukemia
12.5.4.1.1.1. Acute
Lymphocytic Leukemia (ALL)
12.5.4.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
12.5.4.1.1.3. Acute
Myeloid Leukemia (AML)
12.5.4.1.1.4. Chronic
Myeloid Leukemia (CML)
12.5.4.1.1.5. Others
12.5.4.1.2. Lymphoma
12.5.4.1.2.1. Hodgkin's
Lymphoma
12.5.4.1.2.2. Non-Hodgkin's
Lymphoma
12.5.4.1.3. Myeloma
12.5.4.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
12.5.4.2. Germany
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
12.5.4.2.1. Stem Cell Transplantation
12.5.4.2.2. Chemotherapy
12.5.4.2.3. Targeted Therapy
12.5.4.2.4. Immunotherapy
12.5.4.2.5. Radiation Therapy
12.5.4.2.6. Radiosurgery
12.5.4.2.7. Others
12.5.4.3. Germany
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
12.5.4.3.1. Oral
12.5.4.3.2. Intravenous
12.5.4.3.3. Intra-Muscular
12.5.4.3.4. Intrathecal
12.5.4.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
12.5.4.3.6. Others
12.5.5. Italy
12.5.5.1. Italy
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
12.5.5.1.1. Leukemia
12.5.5.1.1.1. Acute
Lymphocytic Leukemia (ALL)
12.5.5.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
12.5.5.1.1.3. Acute
Myeloid Leukemia (AML)
12.5.5.1.1.4. Chronic
Myeloid Leukemia (CML)
12.5.5.1.1.5. Others
12.5.5.1.2. Lymphoma
12.5.5.1.2.1. Hodgkin's
Lymphoma
12.5.5.1.2.2. Non-Hodgkin's
Lymphoma
12.5.5.1.3. Myeloma
12.5.5.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
12.5.5.2. Italy
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
12.5.5.2.1. Stem Cell Transplantation
12.5.5.2.2. Chemotherapy
12.5.5.2.3. Targeted Therapy
12.5.5.2.4. Immunotherapy
12.5.5.2.5. Radiation Therapy
12.5.5.2.6. Radiosurgery
12.5.5.2.7. Others
12.5.5.3. Italy
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
12.5.5.3.1. Oral
12.5.5.3.2. Intravenous
12.5.5.3.3. Intra-Muscular
12.5.5.3.4. Intrathecal
12.5.5.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
12.5.5.3.6. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
12.5.6.1.1. Leukemia
12.5.6.1.1.1. Acute
Lymphocytic Leukemia (ALL)
12.5.6.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
12.5.6.1.1.3. Acute
Myeloid Leukemia (AML)
12.5.6.1.1.4. Chronic
Myeloid Leukemia (CML)
12.5.6.1.1.5. Others
12.5.6.1.2. Lymphoma
12.5.6.1.2.1. Hodgkin's
Lymphoma
12.5.6.1.2.2. Non-Hodgkin's
Lymphoma
12.5.6.1.3. Myeloma
12.5.6.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
12.5.6.2. Nordic
Countries Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
12.5.6.2.1. Stem Cell Transplantation
12.5.6.2.2. Chemotherapy
12.5.6.2.3. Targeted Therapy
12.5.6.2.4. Immunotherapy
12.5.6.2.5. Radiation Therapy
12.5.6.2.6. Radiosurgery
12.5.6.2.7. Others
12.5.6.3. Nordic
Countries Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
12.5.6.3.1. Oral
12.5.6.3.2. Intravenous
12.5.6.3.3. Intra-Muscular
12.5.6.3.4. Intrathecal
12.5.6.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
12.5.6.3.6. Others
12.5.6.4. Nordic
Countries Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
12.5.7.1.1. Leukemia
12.5.7.1.1.1. Acute
Lymphocytic Leukemia (ALL)
12.5.7.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
12.5.7.1.1.3. Acute
Myeloid Leukemia (AML)
12.5.7.1.1.4. Chronic
Myeloid Leukemia (CML)
12.5.7.1.1.5. Others
12.5.7.1.2. Lymphoma
12.5.7.1.2.1. Hodgkin's
Lymphoma
12.5.7.1.2.2. Non-Hodgkin's
Lymphoma
12.5.7.1.3. Myeloma
12.5.7.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
12.5.7.2. Benelux
Union Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment
Type
12.5.7.2.1. Stem Cell Transplantation
12.5.7.2.2. Chemotherapy
12.5.7.2.3. Targeted Therapy
12.5.7.2.4. Immunotherapy
12.5.7.2.5. Radiation Therapy
12.5.7.2.6. Radiosurgery
12.5.7.2.7. Others
12.5.7.3. Benelux
Union Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
12.5.7.3.1. Oral
12.5.7.3.2. Intravenous
12.5.7.3.3. Intra-Muscular
12.5.7.3.4. Intrathecal
12.5.7.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
12.5.7.3.6. Others
12.5.7.4. Benelux
Union Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
12.5.8.1.1. Leukemia
12.5.8.1.1.1. Acute
Lymphocytic Leukemia (ALL)
12.5.8.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
12.5.8.1.1.3. Acute
Myeloid Leukemia (AML)
12.5.8.1.1.4. Chronic
Myeloid Leukemia (CML)
12.5.8.1.1.5. Others
12.5.8.1.2. Lymphoma
12.5.8.1.2.1. Hodgkin's
Lymphoma
12.5.8.1.2.2. Non-Hodgkin's
Lymphoma
12.5.8.1.3. Myeloma
12.5.8.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
12.5.8.2. Rest
of Europe Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
12.5.8.2.1. Stem Cell Transplantation
12.5.8.2.2. Chemotherapy
12.5.8.2.3. Targeted Therapy
12.5.8.2.4. Immunotherapy
12.5.8.2.5. Radiation Therapy
12.5.8.2.6. Radiosurgery
12.5.8.2.7. Others
12.5.8.3. Rest
of Europe Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
12.5.8.3.1. Oral
12.5.8.3.2. Intravenous
12.5.8.3.3. Intra-Muscular
12.5.8.3.4. Intrathecal
12.5.8.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
12.5.8.3.6. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By Type
12.6.3. By
Treatment Type
12.6.4. By
Administration
13. Asia Pacific Hematological Cancers Market Analysis and
Forecasts, 2020 - 2028
13.1. Overview
13.1.1. Asia
Pacific Hematological Cancers Market Revenue (US$ Mn)
13.2. Asia
Pacific Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Leukemia
13.2.1.1. Acute
Lymphocytic Leukemia (ALL)
13.2.1.2. Chronic
Lymphocytic Leukemia (CLL)
13.2.1.3. Acute
Myeloid Leukemia (AML)
13.2.1.4. Chronic
Myeloid Leukemia (CML)
13.2.1.5. Others
13.2.2. Lymphoma
13.2.2.1. Hodgkin's
Lymphoma
13.2.2.2. Non-Hodgkin's
Lymphoma
13.2.3. Myeloma
13.2.4. Others
(Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN))
13.3. Asia
Pacific Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
13.3.1. Stem
Cell Transplantation
13.3.2. Chemotherapy
13.3.3. Targeted
Therapy
13.3.4. Immunotherapy
13.3.5. Radiation
Therapy
13.3.6. Radiosurgery
13.3.7. Others
13.4. Asia
Pacific Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
13.4.1. Oral
13.4.2. Intravenous
13.4.3. Intra-Muscular
13.4.4. Intrathecal
13.4.5. Local
Therapies (Surgery, Radiation Therapy, Topical Therapy, Etc.)
13.4.6. Others
13.5. Asia
Pacific Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
13.5.1.1.1. Leukemia
13.5.1.1.1.1. Acute
Lymphocytic Leukemia (ALL)
13.5.1.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
13.5.1.1.1.3. Acute
Myeloid Leukemia (AML)
13.5.1.1.1.4. Chronic
Myeloid Leukemia (CML)
13.5.1.1.1.5. Others
13.5.1.1.2. Lymphoma
13.5.1.1.2.1. Hodgkin's
Lymphoma
13.5.1.1.2.2. Non-Hodgkin's
Lymphoma
13.5.1.1.3. Myeloma
13.5.1.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
13.5.1.2. China
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
13.5.1.2.1. Stem Cell Transplantation
13.5.1.2.2. Chemotherapy
13.5.1.2.3. Targeted Therapy
13.5.1.2.4. Immunotherapy
13.5.1.2.5. Radiation Therapy
13.5.1.2.6. Radiosurgery
13.5.1.2.7. Others
13.5.1.3. China
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
13.5.1.3.1. Oral
13.5.1.3.2. Intravenous
13.5.1.3.3. Intra-Muscular
13.5.1.3.4. Intrathecal
13.5.1.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
13.5.1.3.6. Others
13.5.2. Japan
13.5.2.1. Japan
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
13.5.2.1.1. Leukemia
13.5.2.1.1.1. Acute
Lymphocytic Leukemia (ALL)
13.5.2.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
13.5.2.1.1.3. Acute
Myeloid Leukemia (AML)
13.5.2.1.1.4. Chronic
Myeloid Leukemia (CML)
13.5.2.1.1.5. Others
13.5.2.1.2. Lymphoma
13.5.2.1.2.1. Hodgkin's
Lymphoma
13.5.2.1.2.2. Non-Hodgkin's
Lymphoma
13.5.2.1.3. Myeloma
13.5.2.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
13.5.2.2. Japan
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
13.5.2.2.1. Stem Cell Transplantation
13.5.2.2.2. Chemotherapy
13.5.2.2.3. Targeted Therapy
13.5.2.2.4. Immunotherapy
13.5.2.2.5. Radiation Therapy
13.5.2.2.6. Radiosurgery
13.5.2.2.7. Others
13.5.2.3. Japan
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
13.5.2.3.1. Oral
13.5.2.3.2. Intravenous
13.5.2.3.3. Intra-Muscular
13.5.2.3.4. Intrathecal
13.5.2.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
13.5.2.3.6. Others
13.5.3. India
13.5.3.1. India
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
13.5.3.1.1. Leukemia
13.5.3.1.1.1. Acute
Lymphocytic Leukemia (ALL)
13.5.3.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
13.5.3.1.1.3. Acute
Myeloid Leukemia (AML)
13.5.3.1.1.4. Chronic
Myeloid Leukemia (CML)
13.5.3.1.1.5. Others
13.5.3.1.2. Lymphoma
13.5.3.1.2.1. Hodgkin's
Lymphoma
13.5.3.1.2.2. Non-Hodgkin's
Lymphoma
13.5.3.1.3. Myeloma
13.5.3.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
13.5.3.2. India
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
13.5.3.2.1. Stem Cell Transplantation
13.5.3.2.2. Chemotherapy
13.5.3.2.3. Targeted Therapy
13.5.3.2.4. Immunotherapy
13.5.3.2.5. Radiation Therapy
13.5.3.2.6. Radiosurgery
13.5.3.2.7. Others
13.5.3.3. India
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
13.5.3.3.1. Oral
13.5.3.3.2. Intravenous
13.5.3.3.3. Intra-Muscular
13.5.3.3.4. Intrathecal
13.5.3.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
13.5.3.3.6. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
13.5.4.1.1. Leukemia
13.5.4.1.1.1. Acute
Lymphocytic Leukemia (ALL)
13.5.4.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
13.5.4.1.1.3. Acute
Myeloid Leukemia (AML)
13.5.4.1.1.4. Chronic
Myeloid Leukemia (CML)
13.5.4.1.1.5. Others
13.5.4.1.2. Lymphoma
13.5.4.1.2.1. Hodgkin's
Lymphoma
13.5.4.1.2.2. Non-Hodgkin's
Lymphoma
13.5.4.1.3. Myeloma
13.5.4.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
13.5.4.2. New
Zealand Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
13.5.4.2.1. Stem Cell Transplantation
13.5.4.2.2. Chemotherapy
13.5.4.2.3. Targeted Therapy
13.5.4.2.4. Immunotherapy
13.5.4.2.5. Radiation Therapy
13.5.4.2.6. Radiosurgery
13.5.4.2.7. Others
13.5.4.3. New
Zealand Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
13.5.4.3.1. Oral
13.5.4.3.2. Intravenous
13.5.4.3.3. Intra-Muscular
13.5.4.3.4. Intrathecal
13.5.4.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
13.5.4.3.6. Others
13.5.5. Australia
13.5.5.1. Australia
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
13.5.5.1.1. Leukemia
13.5.5.1.1.1. Acute
Lymphocytic Leukemia (ALL)
13.5.5.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
13.5.5.1.1.3. Acute
Myeloid Leukemia (AML)
13.5.5.1.1.4. Chronic
Myeloid Leukemia (CML)
13.5.5.1.1.5. Others
13.5.5.1.2. Lymphoma
13.5.5.1.2.1. Hodgkin's
Lymphoma
13.5.5.1.2.2. Non-Hodgkin's
Lymphoma
13.5.5.1.3. Myeloma
13.5.5.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
13.5.5.2. Australia
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
13.5.5.2.1. Stem Cell Transplantation
13.5.5.2.2. Chemotherapy
13.5.5.2.3. Targeted Therapy
13.5.5.2.4. Immunotherapy
13.5.5.2.5. Radiation Therapy
13.5.5.2.6. Radiosurgery
13.5.5.2.7. Others
13.5.5.3. Australia
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
13.5.5.3.1. Oral
13.5.5.3.2. Intravenous
13.5.5.3.3. Intra-Muscular
13.5.5.3.4. Intrathecal
13.5.5.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
13.5.5.3.6. Others
13.5.6. South
Korea
13.5.6.1. South
Korea Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
13.5.6.1.1. Leukemia
13.5.6.1.1.1. Acute
Lymphocytic Leukemia (ALL)
13.5.6.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
13.5.6.1.1.3. Acute
Myeloid Leukemia (AML)
13.5.6.1.1.4. Chronic
Myeloid Leukemia (CML)
13.5.6.1.1.5. Others
13.5.6.1.2. Lymphoma
13.5.6.1.2.1. Hodgkin's
Lymphoma
13.5.6.1.2.2. Non-Hodgkin's
Lymphoma
13.5.6.1.3. Myeloma
13.5.6.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
13.5.6.2. South
Korea Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment
Type
13.5.6.2.1. Stem Cell Transplantation
13.5.6.2.2. Chemotherapy
13.5.6.2.3. Targeted Therapy
13.5.6.2.4. Immunotherapy
13.5.6.2.5. Radiation Therapy
13.5.6.2.6. Radiosurgery
13.5.6.2.7. Others
13.5.6.3. South
Korea Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
13.5.6.3.1. Oral
13.5.6.3.2. Intravenous
13.5.6.3.3. Intra-Muscular
13.5.6.3.4. Intrathecal
13.5.6.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
13.5.6.3.6. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
13.5.7.1.1. Leukemia
13.5.7.1.1.1. Acute
Lymphocytic Leukemia (ALL)
13.5.7.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
13.5.7.1.1.3. Acute
Myeloid Leukemia (AML)
13.5.7.1.1.4. Chronic
Myeloid Leukemia (CML)
13.5.7.1.1.5. Others
13.5.7.1.2. Lymphoma
13.5.7.1.2.1. Hodgkin's
Lymphoma
13.5.7.1.2.2. Non-Hodgkin's
Lymphoma
13.5.7.1.3. Myeloma
13.5.7.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
13.5.7.2. Southeast
Asia Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment
Type
13.5.7.2.1. Stem Cell Transplantation
13.5.7.2.2. Chemotherapy
13.5.7.2.3. Targeted Therapy
13.5.7.2.4. Immunotherapy
13.5.7.2.5. Radiation Therapy
13.5.7.2.6. Radiosurgery
13.5.7.2.7. Others
13.5.7.3. Southeast
Asia Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
13.5.7.3.1. Oral
13.5.7.3.2. Intravenous
13.5.7.3.3. Intra-Muscular
13.5.7.3.4. Intrathecal
13.5.7.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
13.5.7.3.6. Others
13.5.7.4. Southeast
Asia Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.8.1.1. Leukemia
13.5.8.1.1.1. Acute
Lymphocytic Leukemia (ALL)
13.5.8.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
13.5.8.1.1.3. Acute
Myeloid Leukemia (AML)
13.5.8.1.1.4. Chronic
Myeloid Leukemia (CML)
13.5.8.1.1.5. Others
13.5.8.1.2. Lymphoma
13.5.8.1.2.1. Hodgkin's
Lymphoma
13.5.8.1.2.2. Non-Hodgkin's
Lymphoma
13.5.8.1.3. Myeloma
13.5.8.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
13.5.8.2. Rest
of Asia Pacific Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
13.5.8.2.1. Stem Cell Transplantation
13.5.8.2.2. Chemotherapy
13.5.8.2.3. Targeted Therapy
13.5.8.2.4. Immunotherapy
13.5.8.2.5. Radiation Therapy
13.5.8.2.6. Radiosurgery
13.5.8.2.7. Others
13.5.8.3. Rest
of Asia Pacific Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
13.5.8.3.1. Oral
13.5.8.3.2. Intravenous
13.5.8.3.3. Intra-Muscular
13.5.8.3.4. Intrathecal
13.5.8.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy, Etc.)
13.5.8.3.6. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By Type
13.6.3. By
Treatment Type
13.6.4. By
Administration
14. Middle East and Africa Hematological Cancers Market Analysis
and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Middle
East and Africa Hematological Cancers Market Revenue (US$ Mn)
14.2. Middle
East and Africa Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Type
14.2.1. Leukemia
14.2.1.1. Acute
Lymphocytic Leukemia (ALL)
14.2.1.2. Chronic
Lymphocytic Leukemia (CLL)
14.2.1.3. Acute
Myeloid Leukemia (AML)
14.2.1.4. Chronic
Myeloid Leukemia (CML)
14.2.1.5. Others
14.2.2. Lymphoma
14.2.2.1. Hodgkin's
Lymphoma
14.2.2.2. Non-Hodgkin's
Lymphoma
14.2.3. Myeloma
14.2.4. Others
(Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN))
14.3. Middle
East and Africa Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
14.3.1. Stem
Cell Transplantation
14.3.2. Chemotherapy
14.3.3. Targeted
Therapy
14.3.4. Immunotherapy
14.3.5. Radiation
Therapy
14.3.6. Radiosurgery
14.3.7. Others
14.4. Middle
East and Africa Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
14.4.1. Oral
14.4.2. Intravenous
14.4.3. Intra-Muscular
14.4.4. Intrathecal
14.4.5. Local
Therapies (Surgery, Radiation Therapy, Topical Therapy, Etc.)
14.4.6. Others
14.5. Middle
East and Africa Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
14.5.1.1.1. Leukemia
14.5.1.1.1.1. Acute
Lymphocytic Leukemia (ALL)
14.5.1.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
14.5.1.1.1.3. Acute
Myeloid Leukemia (AML)
14.5.1.1.1.4. Chronic
Myeloid Leukemia (CML)
14.5.1.1.1.5. Others
14.5.1.1.2. Lymphoma
14.5.1.1.2.1. Hodgkin's
Lymphoma
14.5.1.1.2.2. Non-Hodgkin's
Lymphoma
14.5.1.1.3. Myeloma
14.5.1.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms
(MPN))
14.5.1.2. Saudi
Arabia Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
14.5.1.2.1. Stem Cell Transplantation
14.5.1.2.2. Chemotherapy
14.5.1.2.3. Targeted Therapy
14.5.1.2.4. Immunotherapy
14.5.1.2.5. Radiation Therapy
14.5.1.2.6. Radiosurgery
14.5.1.2.7. Others
14.5.1.3. Saudi
Arabia Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
14.5.1.3.1. Oral
14.5.1.3.2. Intravenous
14.5.1.3.3. Intra-Muscular
14.5.1.3.4. Intrathecal
14.5.1.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
14.5.1.3.6. Others
14.5.2. UAE
14.5.2.1. UAE
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
14.5.2.1.1. Leukemia
14.5.2.1.1.1. Acute
Lymphocytic Leukemia (ALL)
14.5.2.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
14.5.2.1.1.3. Acute
Myeloid Leukemia (AML)
14.5.2.1.1.4. Chronic
Myeloid Leukemia (CML)
14.5.2.1.1.5. Others
14.5.2.1.2. Lymphoma
14.5.2.1.2.1. Hodgkin's
Lymphoma
14.5.2.1.2.2. Non-Hodgkin's
Lymphoma
14.5.2.1.3. Myeloma
14.5.2.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
14.5.2.2. UAE
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
14.5.2.2.1. Stem Cell Transplantation
14.5.2.2.2. Chemotherapy
14.5.2.2.3. Targeted Therapy
14.5.2.2.4. Immunotherapy
14.5.2.2.5. Radiation Therapy
14.5.2.2.6. Radiosurgery
14.5.2.2.7. Others
14.5.2.3. UAE
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
14.5.2.3.1. Oral
14.5.2.3.2. Intravenous
14.5.2.3.3. Intra-Muscular
14.5.2.3.4. Intrathecal
14.5.2.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
14.5.2.3.6. Others
14.5.3. Egypt
14.5.3.1. Egypt
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
14.5.3.1.1. Leukemia
14.5.3.1.1.1. Acute
Lymphocytic Leukemia (ALL)
14.5.3.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
14.5.3.1.1.3. Acute
Myeloid Leukemia (AML)
14.5.3.1.1.4. Chronic
Myeloid Leukemia (CML)
14.5.3.1.1.5. Others
14.5.3.1.2. Lymphoma
14.5.3.1.2.1. Hodgkin's
Lymphoma
14.5.3.1.2.2. Non-Hodgkin's
Lymphoma
14.5.3.1.3. Myeloma
14.5.3.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
14.5.3.2. Egypt
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
14.5.3.2.1. Stem Cell Transplantation
14.5.3.2.2. Chemotherapy
14.5.3.2.3. Targeted Therapy
14.5.3.2.4. Immunotherapy
14.5.3.2.5. Radiation Therapy
14.5.3.2.6. Radiosurgery
14.5.3.2.7. Others
14.5.3.3. Egypt
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
14.5.3.3.1. Oral
14.5.3.3.2. Intravenous
14.5.3.3.3. Intra-Muscular
14.5.3.3.4. Intrathecal
14.5.3.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
14.5.3.3.6. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
14.5.4.1.1. Leukemia
14.5.4.1.1.1. Acute
Lymphocytic Leukemia (ALL)
14.5.4.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
14.5.4.1.1.3. Acute
Myeloid Leukemia (AML)
14.5.4.1.1.4. Chronic
Myeloid Leukemia (CML)
14.5.4.1.1.5. Others
14.5.4.1.2. Lymphoma
14.5.4.1.2.1. Hodgkin's
Lymphoma
14.5.4.1.2.2. Non-Hodgkin's
Lymphoma
14.5.4.1.3. Myeloma
14.5.4.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
14.5.4.2. Kuwait
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
14.5.4.2.1. Stem Cell Transplantation
14.5.4.2.2. Chemotherapy
14.5.4.2.3. Targeted Therapy
14.5.4.2.4. Immunotherapy
14.5.4.2.5. Radiation Therapy
14.5.4.2.6. Radiosurgery
14.5.4.2.7. Others
14.5.4.3. Kuwait
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
14.5.4.3.1. Oral
14.5.4.3.2. Intravenous
14.5.4.3.3. Intra-Muscular
14.5.4.3.4. Intrathecal
14.5.4.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
14.5.4.3.6. Others
14.5.5. South
Africa
14.5.5.1. South
Africa Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
14.5.5.1.1. Leukemia
14.5.5.1.1.1. Acute
Lymphocytic Leukemia (ALL)
14.5.5.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
14.5.5.1.1.3. Acute
Myeloid Leukemia (AML)
14.5.5.1.1.4. Chronic
Myeloid Leukemia (CML)
14.5.5.1.1.5. Others
14.5.5.1.2. Lymphoma
14.5.5.1.2.1. Hodgkin's
Lymphoma
14.5.5.1.2.2. Non-Hodgkin's
Lymphoma
14.5.5.1.3. Myeloma
14.5.5.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
14.5.5.2. South
Africa Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
14.5.5.2.1. Stem Cell Transplantation
14.5.5.2.2. Chemotherapy
14.5.5.2.3. Targeted Therapy
14.5.5.2.4. Immunotherapy
14.5.5.2.5. Radiation Therapy
14.5.5.2.6. Radiosurgery
14.5.5.2.7. Others
14.5.5.3. South
Africa Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
14.5.5.3.1. Oral
14.5.5.3.2. Intravenous
14.5.5.3.3. Intra-Muscular
14.5.5.3.4. Intrathecal
14.5.5.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
14.5.5.3.6. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa Hematological Cancers Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.6.1.1. Leukemia
14.5.6.1.1.1. Acute
Lymphocytic Leukemia (ALL)
14.5.6.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
14.5.6.1.1.3. Acute
Myeloid Leukemia (AML)
14.5.6.1.1.4. Chronic
Myeloid Leukemia (CML)
14.5.6.1.1.5. Others
14.5.6.1.2. Lymphoma
14.5.6.1.2.1. Hodgkin's
Lymphoma
14.5.6.1.2.2. Non-Hodgkin's
Lymphoma
14.5.6.1.3. Myeloma
14.5.6.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
14.5.6.2. Rest
of Middle East & Africa Hematological Cancers Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.5.6.2.1. Stem Cell Transplantation
14.5.6.2.2. Chemotherapy
14.5.6.2.3. Targeted Therapy
14.5.6.2.4. Immunotherapy
14.5.6.2.5. Radiation Therapy
14.5.6.2.6. Radiosurgery
14.5.6.2.7. Others
14.5.6.3. Rest
of Middle East & Africa Hematological Cancers Market Revenue (US$ Mn) and
Forecasts, By Administration
14.5.6.3.1. Oral
14.5.6.3.2. Intravenous
14.5.6.3.3. Intra-Muscular
14.5.6.3.4. Intrathecal
14.5.6.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
14.5.6.3.6. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By Type
14.6.3. By
Treatment Type
14.6.4. By
Administration
15. Latin America Hematological Cancers Market Analysis and
Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Latin
America Hematological Cancers Market Revenue (US$ Mn)
15.2. Latin
America Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Leukemia
15.2.1.1. Acute
Lymphocytic Leukemia (ALL)
15.2.1.2. Chronic
Lymphocytic Leukemia (CLL)
15.2.1.3. Acute
Myeloid Leukemia (AML)
15.2.1.4. Chronic
Myeloid Leukemia (CML)
15.2.1.5. Others
15.2.2. Lymphoma
15.2.2.1. Hodgkin's
Lymphoma
15.2.2.2. Non-Hodgkin's
Lymphoma
15.2.3. Myeloma
15.2.4. Others
(Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN))
15.3. Latin
America Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
15.3.1. Stem
Cell Transplantation
15.3.2. Chemotherapy
15.3.3. Targeted
Therapy
15.3.4. Immunotherapy
15.3.5. Radiation
Therapy
15.3.6. Radiosurgery
15.3.7. Others
15.4. Latin
America Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By
Administration
15.4.1. Oral
15.4.2. Intravenous
15.4.3. Intra-Muscular
15.4.4. Intrathecal
15.4.5. Local
Therapies (Surgery, Radiation Therapy, Topical Therapy, Etc.)
15.4.6. Others
15.5. Latin
America Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
15.5.1.1.1. Leukemia
15.5.1.1.1.1. Acute
Lymphocytic Leukemia (ALL)
15.5.1.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
15.5.1.1.1.3. Acute
Myeloid Leukemia (AML)
15.5.1.1.1.4. Chronic
Myeloid Leukemia (CML)
15.5.1.1.1.5. Others
15.5.1.1.2. Lymphoma
15.5.1.1.2.1. Hodgkin's
Lymphoma
15.5.1.1.2.2. Non-Hodgkin's
Lymphoma
15.5.1.1.3. Myeloma
15.5.1.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
15.5.1.2. Brazil
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
15.5.1.2.1. Stem Cell Transplantation
15.5.1.2.2. Chemotherapy
15.5.1.2.3. Targeted Therapy
15.5.1.2.4. Immunotherapy
15.5.1.2.5. Radiation Therapy
15.5.1.2.6. Radiosurgery
15.5.1.2.7. Others
15.5.1.3. Brazil
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
15.5.1.3.1. Oral
15.5.1.3.2. Intravenous
15.5.1.3.3. Intra-Muscular
15.5.1.3.4. Intrathecal
15.5.1.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
15.5.1.3.6. Others
15.5.2. Argentina
15.5.2.1. Argentina
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Type
15.5.2.1.1. Leukemia
15.5.2.1.1.1. Acute
Lymphocytic Leukemia (ALL)
15.5.2.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
15.5.2.1.1.3. Acute
Myeloid Leukemia (AML)
15.5.2.1.1.4. Chronic
Myeloid Leukemia (CML)
15.5.2.1.1.5. Others
15.5.2.1.2. Lymphoma
15.5.2.1.2.1. Hodgkin's
Lymphoma
15.5.2.1.2.2. Non-Hodgkin's
Lymphoma
15.5.2.1.3. Myeloma
15.5.2.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
15.5.2.2. Argentina
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Treatment Type
15.5.2.2.1. Stem Cell Transplantation
15.5.2.2.2. Chemotherapy
15.5.2.2.3. Targeted Therapy
15.5.2.2.4. Immunotherapy
15.5.2.2.5. Radiation Therapy
15.5.2.2.6. Radiosurgery
15.5.2.2.7. Others
15.5.2.3. Argentina
Hematological Cancers Market Revenue (US$ Mn) and Forecasts, By Administration
15.5.2.3.1. Oral
15.5.2.3.2. Intravenous
15.5.2.3.3. Intra-Muscular
15.5.2.3.4. Intrathecal
15.5.2.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
15.5.2.3.6. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America Hematological Cancers Market Revenue (US$ Mn) and Forecasts,
By Type
15.5.3.1.1. Leukemia
15.5.3.1.1.1. Acute
Lymphocytic Leukemia (ALL)
15.5.3.1.1.2. Chronic
Lymphocytic Leukemia (CLL)
15.5.3.1.1.3. Acute
Myeloid Leukemia (AML)
15.5.3.1.1.4. Chronic
Myeloid Leukemia (CML)
15.5.3.1.1.5. Others
15.5.3.1.2. Lymphoma
15.5.3.1.2.1. Hodgkin's
Lymphoma
15.5.3.1.2.2. Non-Hodgkin's
Lymphoma
15.5.3.1.3. Myeloma
15.5.3.1.4. Others (Myelodysplastic Syndromes (MDS), Myeloproliferative
Neoplasms (MPN))
15.5.3.2. Rest
of Latin America Hematological Cancers Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
15.5.3.2.1. Stem Cell Transplantation
15.5.3.2.2. Chemotherapy
15.5.3.2.3. Targeted Therapy
15.5.3.2.4. Immunotherapy
15.5.3.2.5. Radiation Therapy
15.5.3.2.6. Radiosurgery
15.5.3.2.7. Others
15.5.3.3. Rest
of Latin America Hematological Cancers Market Revenue (US$ Mn) and Forecasts,
By Administration
15.5.3.3.1. Oral
15.5.3.3.2. Intravenous
15.5.3.3.3. Intra-Muscular
15.5.3.3.4. Intrathecal
15.5.3.3.5. Local Therapies (Surgery, Radiation Therapy, Topical Therapy,
Etc.)
15.5.3.3.6. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Type
15.6.3. By
Treatment Type
15.6.4. By
Administration
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2019
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. AbbVie
Inc.
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Bristol-Myers
Squibb Company
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. F.
Hoffmann-La Roche Ltd
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. GlaxoSmithKline
plc
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. HK inno.N
Corp.
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Johnson
& Johnson Services, Inc
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Novartis
AG
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Pfizer
Inc.
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Sanofi
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Takeda
Pharmaceutical Company Limited
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. Other Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.